60岁以下患者生物瓣主动脉瓣置换的耐久性——前瞻性INDURE注册研究1年随访结果
INDURE注册研究为前瞻性多中心注册,评估60岁以下接受生物瓣主动脉瓣置换患者的1年结局。共记录421例患者,平均年龄53.5岁,1年全因死亡率无事件率为98.3%(95%CI 97.1; 99.6),无患者发生结构性瓣膜退化3期(VARC-3),平均主动脉瓣压差12.6 mmHg,有效瓣口面积1.9 cm2,生活质量在6个月时显著提高并维持至1年。
要点
- 60岁以下患者生物瓣主动脉瓣置换术后1年全因死亡率无事件率为98.3%(95%CI 97.1; 99.6)。
- 1年内无患者发生结构性瓣膜退化3期(VARC-3)。
- 1年平均主动脉瓣压差12.6 mmHg,有效瓣口面积1.9 cm2。
核心结论
- INSPIRIS RESILIA瓣膜1年数据表明安全性良好、血流动力学性能优异且生活质量早期改善。
研究设计与样本
- INSPIRIS RESILIA耐久性注册研究(INDURE)为前瞻性多中心注册研究。
- 纳入计划行外科主动脉瓣置换术伴或不伴升主动脉置换和/或冠状动脉旁路移植术的60岁以下患者。
- 共记录421例患者,平均年龄53.5岁,76.5%为男性,27.2%为NYHA III/IV级。
主要发现
- 30天内结局包括心血管相关死亡0.7%、时间相关瓣膜安全性(VARC-2)5.8%、血栓栓塞事件1.7%、瓣膜相关危及生命出血(VARC-2)4.3%和永久起搏器植入3.8%。
- 生活质量在6个月时显著提高并维持至1年。
- 1年全因死亡率无事件率为98.3%(95%CI 97.1; 99.6),NYHA I级比例为81.8%,基线为21.9%。
- 无患者发生结构性瓣膜退化3期(VARC-3)。
- 1年平均主动脉瓣压差为12.6 mmHg,有效瓣口面积为1.9 cm2。
关键数值与推荐
- 1年全因死亡率无事件率为98.3%(95%CI 97.1; 99.6)。
- NYHA I级比例从基线21.9%升至1年81.8%。
- 1年平均主动脉瓣压差12.6 mmHg,有效瓣口面积1.9 cm2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We report 1-year safety and clinical outcomes in patients <60 years undergoing bioprosthetic surgical aortic valve intervention. METHODS: The INSPIRIS RESILIA Durability Registry is a prospective, multicentre registry to assess clinical outcomes of patients <60 years. Patients with planned SAVR with or without concomitant replacement of the ascending aorta and/or coronary bypass surgery were included. Time-related valve safety, haemodynamic performance and quality of life (QoL) at 1 year were assessed. RESULTS: A total of 421 patients were documented with a mean age of 53.5 years, 76.5% being male and 27.2% in NYHA class III/IV. Outcomes within 30 days included cardiovascular-related mortality (0.7%), time-related valve safety (VARC-2; 5.8%), thromboembolic events (1.7%), valve-related life-threatening bleeding (VARC-2; 4.3%) and permanent pacemaker implantation (3.8%). QoL was significantly increased at 6 months and sustained at 1 year. Freedom from all-cause mortality at 1 year was 98.3% (95% confidence interval 97.1; 99.6) and 81.8% were NYHA I versus 21.9% at baseline. No patient developed structural valve deterioration stage 3 (VARC-3). The mean aortic pressure gradient was 12.6 mmHg at 1 year and the effective orifice area was 1.9 cm2. CONCLUSIONS: The 1-year data from the INSPIRIS RESILIA valve demonstrate good safety and excellent haemodynamic performance as well as an early QoL improvement. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov: NCT03666741.
引用
- Meuris B, Roussel JC, Borger MA, et al. Durability of bioprosthetic aortic valve replacement in patients under the age of 60 years - 1-year follow-up from the prospective INDURE registry. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 37462612. doi:10.1093/icvts/ivad115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。